Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Recurrence 1Oligodendroglioma 1Melanoma 1Lung Neoplasms 1Glioblastoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 25Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × paclitaxel-Angiopep-2 conjugate × Clear all
NCT00539344 2014-07-31

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Angiochem Inc

Phase 1 Completed
63 enrolled
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡